A novel vaccine, purported to reverse aging, has been administered to a human subject. This represents a significant breakthrough in the field of longevity science. For the first time, there is a tangible prospect of demonstrating that epigenetic reprogramming, which rejuvenates aging cells, can indeed decelerate the aging process. This development was reported by BI.
On Tuesday, Life Biosciences announced that the inaugural patient received an injection designed for cellular reprogramming and the combat of age-related diseases. Previously, this method had only undergone testing in animals. Now, this so-called “elixir of youth” has been introduced into a human body. Scientists will now monitor the patient’s condition and analyze the initial changes observed.
A successful initial human trial could herald a new era in anti-aging therapies. The primary objective is cellular rejuvenation and the enhancement of DNA expression. The injection was administered directly into the eyeball of a patient diagnosed with glaucoma. Over a six-month period, researchers will assess the therapy’s efficacy, while medical professionals will evaluate its safety profile.
Earlier, KP.RU reported that Life Biosciences had commenced clinical trials for ER-100, a gene therapy aimed at treating age-related ocular conditions. The intended outcome of this therapy is to restore the correct epigenetic markers to the cells.
About the Author
